GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » YoY EPS Growth

Theriva Biologics (FRA:SFY) YoY EPS Growth : 1.43% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Theriva Biologics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Theriva Biologics's YoY EPS Growth for the quarter that ended in Mar. 2024 was 1.43%.

Theriva Biologics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.28.


Theriva Biologics YoY EPS Growth Historical Data

The historical data trend for Theriva Biologics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics YoY EPS Growth Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.29 38.49 69.00 26.46 15.52

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 -18.49 41.25 26.99 1.43

Theriva Biologics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Theriva Biologics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.045--1.237)/ | -1.237 |
=15.52 %

Theriva Biologics's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.276--0.28)/ | -0.28 |
=1.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (FRA:SFY) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-25-2022